Targeted Anticancer Flashcards
Target of Bevacizumab
VEGF
2 TKI’s associated with cardiovascular dysfunction
Lapatinib, Nilotinib
Administration of Bortezomib
IV Bolus or SC Injection
All currently available Tyrosine Kinases inhibitors work by
Binding to the highly-conserved ATP-binding site
Bevacizumab Toxicities
HTN, CHR, Pulmonary Hemorrhage, GI perforation
Block heterodimerization of Her2 and Her3
MOA of Pertuzumab
Blood dyscriasis should be immediately associated with
Cytotoxic Agents
Function of 26-S proteosome
Inhibit degradation of proteins marked by ubiquitin
MOA of Everolimus
mTOR inhibitor
MOA of Ipiliumumab
Stimuates T-Cell activation by binding CTLA-4 on surface
MOA of Pertuzumab
Block heterodimerization of Her2 and Her3
MOA of Sirolimus
mTOR inhibitor
MOA of Temsirolimus
mTOR inhibitor
mTOR inhibitors
Sirolimus, Everolimus, Temsirolimus
Patients with mutations in KRAS and BRAF are less likely to respond to
Anti-EGFR therapies